We further assessed differentiation-state enrichments following MEK or PI3K/mTOR inhibition by analyzing treated cell populations using RNA-sequencing and geneset enrichment analysis (GSEA) for 32 curated genesets relating to normal breast cell states2,31,39, breast cancer subtypes40–43, and breast cancer proliferation40,44 (Supplementary Data 3 “Breast Phenotype Genesets”). This evidence concerns the gene MTOR and breast cancer.